Hemostasis activation markers in acute renal failure

Area of Science:

• Nephrology
• Hematology
• Clinical Chemistry

Background:

• Acute renal failure (ARF) can lead to elevated plasma concentrations of hemostasis activation markers.
• This elevation may result from impaired renal elimination rather than true hemostasis activation.
• The validity of specific markers in ARF requires careful assessment.

Purpose of the Study:

• To evaluate the reliability of fibrinopeptide A, thrombin-antithrombin III complex, and beta-thromboglobulin as markers for hemostasis activation in ARF patients.
• To determine if elevated marker levels in ARF are solely due to renal dysfunction or indicate underlying hemostasis activation.

Main Methods:

• Studied 32 patients with ARF before renal replacement therapy.
• Measured plasma concentrations of fibrinopeptide A, thrombin-antithrombin III complex, and beta-thromboglobulin.
• Assessed correlations between markers, serum creatinine, and the presence of disseminated intravascular coagulation (DIC).

Main Results:

• Significant elevations in fibrinopeptide A, thrombin-antithrombin III complex, and beta-thromboglobulin were observed in ARF patients.
• No correlation was found between marker levels and serum creatinine.
• Higher marker concentrations were noted in patients with DIC compared to those without.
• Fibrinopeptide A and beta-thromboglobulin/creatinine coefficient correlated with thrombin-antithrombin III complex levels.

Conclusions:

• Fibrinopeptide A and beta-thromboglobulin/creatinine coefficient, in conjunction with thrombin-antithrombin III complex, are reliable markers for hemostasis activation in ARF.
• The observed elevations are not directly related to the degree of kidney dysfunction but reflect actual hemostasis activation.
• These markers maintain their utility despite varying elimination pathways in ARF.